

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
MIDCAP FINANCIAL SBIC, LP		05/09/2013	LIMITED PARTNERSHIP: DELAWARE

RECEIVING PARTY DATA

Name:	REGADO BIOSCIENCES, INC.
Street Address:	318 Blackwell Street
Internal Address:	Suite 130
City:	Durham
State/Country:	NORTH CAROLINA
Postal Code:	27701
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 6

Property Type	Number	Word Mark
Serial Number:	77658131	REGADO BIOSCIENCES
Serial Number:	77658125	REGADO BIOSCIENCES
Serial Number:	77655445	WE TAKE SCIENCE TO HEART
Serial Number:	77658139	REGADO
Serial Number:	77658108	REGADO
Serial Number:	77652298	TAKING SCIENCE TO HEART

CORRESPONDENCE DATA

Fax Number: 9735972400
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Phone: 973-597-2500
 Email: lstrademark@lowenstein.com
 Correspondent Name: Vanessa A. Ignacio, Esq.
 Address Line 1: Lowenstein Sandler LLP

CH \$165.00 77658131

Address Line 2: 65 Livingston Avenue
Address Line 4: Roseland, NEW JERSEY 07068-1791

ATTORNEY DOCKET NUMBER:	22318.15
NAME OF SUBMITTER:	Vanessa A. Ignacio, Esq.
Signature:	/Vanessa A. Ignacio/
Date:	05/14/2013

Total Attachments: 11
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page1.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page2.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page3.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page4.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page5.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page6.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page7.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page8.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page9.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page10.tif
source=MIDCAP FINANCIAL SBIC, LP to REGADO BIOSCIENCES, INC. (Release of Security Interest)#page11.tif

RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS

THIS RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS (this "Release") is made as of May 9, 2013 ("Effective Date") by MIDCAP FINANCIAL SBIC, LP, in its capacity as Agent for the Lenders ("Grantee"), in favor of REGADO BIOSCIENCES, INC. ("Grantor").

WHEREAS, Grantor is a borrower under that certain Loan and Security Agreement, dated as of May 25, 2011, by and among Grantor, the other Persons signatory thereto from time to time as Loan Parties, the Persons parties thereto from time to time as Lenders, and MidCap Financial SBIC, LP, as Agent for the Lenders (as amended, and as may be further amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"). All capitalized terms used in this letter agreement which are not defined herein shall have the same meanings given such terms in the Loan Agreement;

WHEREAS, pursuant to the terms and conditions of that certain Intellectual Property Security Agreement dated as of May 25, 2011 (as amended, restated, supplemented or otherwise modified from time to time, the "IP Security Agreement"), Grantor granted, assigned, conveyed, mortgaged, pledged, hypothecated and transferred to Grantee, and granted to Grantee, a security interest in all of Grantor's right, title and interest in and to the Patents (as defined in the IP Security Agreement, the "Patents") and Trademarks (as defined in the IP Security Agreement, the "Trademarks");

WHEREAS, the IP Security Agreement was recorded with the United States Patent and Trademark Office on May 27, 2011 at Reel/Frame 026357/0267 and at Reel/Frame 004550/0210;

WHEREAS, pursuant to the terms and conditions of that certain payoff letter, dated as of May 9, 2013, by and among Grantee and Grantor, Grantee has consented to the release of the Lien on the Collateral including, without limitation, the Collateral listed on Schedule 1 attached hereto (collectively, the "Intellectual Property Collateral"); and

WHEREAS, Grantee desires to release its Lien in the Intellectual Property Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby covenants and agrees as follows:

1. Grantee's Lien in the Intellectual Property Collateral granted pursuant to the Loan Agreement and the IP Security Agreement respectively is hereby terminated and released.
2. To the extent Grantee retains any such interest, Grantee hereby assigns, transfers and conveys to Grantor, all of Grantee's right, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest in the each of the Patents and Trademarks, including, without limitation, the entire right, title and interest in and to each of the Patents and Trademarks, all renewals thereof, all proceeds of infringement suits, the right to sue for past, present and future infringements, and all rights corresponding thereto and the goodwill of the business to which the

Intellectual Property Collateral relates. Such assignment, transfer and conveyance by Grantee is made without any representation or warranty (express or implied) by Grantee.

3. Grantee hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release, all at the expense of Grantor. Grantee authorizes Grantor (or its agents) to file such documentation as is necessary to effect the releases of the Intellectual Property Collateral granted hereunder.

4. This Release may be executed in counterparts, each of which will be deemed an original, but all of which together constitute one and the same original. Delivery of an executed counterpart of a signature page to this Release by facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart of this Release.


5. THIS RELEASE SHALL BE DEEMED TO BE A CONTRACT MADE UNDER AND GOVERNED BY THE LAWS OF THE STATE OF MARYLAND WITHOUT GIVING EFFECT TO THE PRINCIPLES OF CONFLICT OF LAWS THAT WOULD APPLY THE LAWS OF ANOTHER JURISDICTION.

[Remainder of page intentionally blank; signature page follows.]

IN WITNESS WHEREOF, Grantee has caused this Release to be executed by its duly authorized representative as of the Effective Date.

MIDCAP FINANCIAL SBIC, LP

By: MIDCAP FINANCIAL SBIC, GP, as
Grantee

By: 
Name: Luis Viera
Title: Authorized Signatory / Managing Director

RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS
SIGNATURE PAGE

TRADEMARK
REEL: 005027 FRAME: 0333

ACCEPTED and AGREED:

REGADO BIOSCIENCES, INC.

By: 

Name: Chris Covert

Title: VP Finance

RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS
SIGNATURE PAGE

TRADEMARK
REEL: 005027 FRAME: 0334

SCHEDULE I

TRADEMARK REGISTRATIONS

Serial Number	Registration Number	Mark
77/658,131	3711403	REGADO BIOSCIENCES
77/658,125	3711402	REGADO BIOSCIENCES
77/655,445	3711393	WE TAKE SCIENCE TO HEART
77/658,139		REGADO
77/658,108		REGADO
77/462,077		REGADO BIOSCIENCES THE ANTIDOTE CONTROL COMPANY
77/652,298		TAKING SCIENCE TO HEART

PATENT REGISTRATIONS

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
10815-8001	ATI No. 10815-105002	US	Expired	60/235,654	26-Sep-08				
10815-8001 US00	ATI No. 10815-105005	US	Granted	09/963,827	26-Sep-07/2003-0175705		18-Sep-03	7,312,325	25-Dec-07
10815-8001 US01	ATI No. 10815-105017	US	Granted	11/925,641	26-Oct-07/2008-0182809		31-Jul-08	7,812,001	12-Oct-10
10815-8001 US02	ATI No. 10815-105018	US	Granted	11/925,645	26-Oct-07/2008-0221053		11-Sep-08	7,741,307	22-Jun-10
10815-8001 US03	ATI No. 10815-105019	US	Granted	11/925,648	26-Oct-07/2008-0207546		28-Aug-08	7,776,836	17-Aug-10
10815-8001 US04	ATI No. 10815-105020	US	Granted	11/925,651	26-Oct-07/2008-0200413		21-Aug-08	7,858,591	28-Dec-10
10815-8001 US05	ATI No. 10815-105021	US	Granted	11/936,015	06-Nov-07/2009-0163429		25-Jun-09	7,776,837	17-Aug-10
10815-8001 US06	ATI No. 10815-105020	US	Pending	12/971,695	17-Dec-10				
10815-8001 WO00	ATI No. 10815-105006	PCT	National	PCT/US01/30804	26-Sep-01/WO/2002/026932		04-Apr-02		

4758132_1

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
10815-8001.AU00	ATL No. 10815-105006 AU	AU	Granted	2001296305	26-Sep-01			2001296305	20-Mar-08
10815-8001.AU01	ATL No. 10815-105006 AU	AU	Pending	2007201745	26-Sep-01				
10815-8001.AU02	NA	AU							
10815-8001.CA00	ATL No. 10815-105006 CA	CA	Pending	2,425,208	26-Sep-01				
10815-8001.EP00	ATL No. 10815-105006 EP	EP	Published	01977167.4	26-Sep-01	1330544	30-Jul-03		
10815-8001.EP01	ATL No. 10815-105006 EP	EP	Pending	10185481.8	26-Sep-01				
10815-8001.EP02	AUL No. 10815-105006 EP	EP	Pending	10185469.3	01-Oct-10				
MOBILIZATORS OF PHARMACOLOGICAL AGENTS									
10815-8002	ATL No. 10815-105002	US	Expired	60293231	25-May-01				
10815-8002.US00	ATL No. 10815-105002	US	Expired	60331037	07-Nov-01				
10815-8002.US01	ATL No. 10815-105008	US	Granted	10755233	28-May-02	0083294	01-May-03	7,300,922	27-Nov-07
10815-8002.US02	ATL No. 10815-105008	US	Published	11,789,992	26-Apr-07	0061339	28-Feb-08		
10815-8002.US05	ATL No. 10815-105027	US	Published	12,637,467	14-Dec-09	0249217	30-Sep-10		
10815-8002.WO00	ATL No. 10815-105004	PCT	National	PCT/US2002/16555	28-May-02	WO/2002/096926	05-Dec-02		
10815-8002.AT00	ATL No. 10815-105004	AT	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.AU00	ATL No. 10815-105004	AU	Granted	2002312059	28-May-02			2002312059	30-Apr-09
10815-8002.AU01	ATL No. 10815-105004	AU	Pending	2009200056	28-May-02				
10815-8002.BE00	ATL No. 10815-105004	BE	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.CA00	ATL No. 10815-105004	CA	Pending	2,448,567	28-May-02				
10815-8002.CH00	ATL No. 10815-105004	CH	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.CY00	ATL No. 10815-105004	CY	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.DE00	ATL No. 10815-105004	DE	Granted	02739409.7	28-May-02	1401853	31-Mar-04	P60217768.4-08	22-Sep-10

47581232_1

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
	DE								
10815-8002-DK00	ATL No. 10815-105004 DK	DK	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-EP00	ATL No. 10815-105004 EP	EP	Regional	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-EP01	ATL No. 10815-105004 EP	EP	Published	09156205.8	28-May-02/2070939		17-Jun-09		
10815-8002-EP02	ATL No. 10815-105004 EP	EP	Pending	10181597.5	28-May-02				
10815-8002-ES00	ATL No. 10815-105004 ES	ES	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-FI00	ATL No. 10815-105004 FI	FI	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-FR00	ATL No. 10815-105004 FR	FR	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-GB00	ATL No. 10815-105004 GB	GB	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-GR00	ATL No. 10815-105004 GR	GR	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-HK00	ATL No. 10815-105004 HK	HK	Published	09111516.3	09-Dec-09/131623A		29-Jan-10		
10815-8002-IE00	ATL No. 10815-105004 IE	IE	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-IL00	ATL No. 10815-105004 IL	IL	Granted	159053	28-May-02/159053				
10815-8002-IN00	ATL No. 10815-105004 IN	IN	Granted	02209/DELNP/2003	28-May-02			221070	16-Jun-08
10815-8002-IN01	ATL No. 10815-105004 IN	India	Pending	3071/DELNP/2008	28-May-02				
10815-8002-IN02	ATL No. 10815-105004 IN	IN	Pending	3078/DELNP/2008	15-Apr-08				
10815-8002-IT00	ATL No. 10815-105004 IT	IT	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002-JP00	ATL No. 10815-105004 JP	JP	Published	2003300105	28-May-02/2005592596		27-Jan-05		
10815-8002-JP01	ATL No. 10815-105004 JP	JP	Published	200968055	19-Mar-02/009185035		20-Aug-09		
10815-8002-KR00	ATL No. 10815-105004 KR	KR	Abandoned	1020037015418	28-May-02				
10815-8002-LU00	ATL No. 10815-105004 LU	LU	Granted	02739409.7	28-May-02/1401853	1401853	31-Mar-04	1401853	22-Sep-10

47581232_1

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
	LU								
10815-8902.MC00	ATL No. 10815-105004 MC	MC	Granted	02759409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8902.NL00	ATL No. 10815-105004 NL	NL	Granted	02759409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8902.PT00	ATL No. 10815-105004 PT	PT	Granted	02759409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8902.SE00	ATL No. 10815-105004 SE	SE	Granted	02759409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8902.SG00	ATL No. 10815-105004 SG	SG	Abandoned	20030703.5	28-May-02				
10815-8902.SG01	ATL No. 10815-105004 SG	SG	Published	200702457.3	28-May-02	57961	29-Jan-10		
10815-8902.TR00	ATL No. 10815-105004 TR	TR	Granted	02759409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
IMPROVED MODULATORS OF COAGULATION FACTORS									
10815-8903	ATL No. 10815-105003	US	Form Filed	60-564,873	22-Apr-04				
10815-8903.US00	ATL No. 10815-105003	US	Granted	41113,378	22-Apr-02	006-0040881	23-Feb-06	7,304,041	04-Dec-07
10815-8903.US01	ATL No. 10815-105003	US	Granted	11-821,183	22-Jun-07	008-0153769	26-Jun-08	7,723,315	25-May-10
10815-8903.US02	ATL No. 10815-105037	US	Abandoned	12-779,968	23-Mar-10				
10815-8903.US03	ATL No. 10815-105037	US	Published	12-758,565	12-Apr-10	US-2010-0197900	05-Aug-10		
10815-8903.WO00	ATL No. 10815-105003	PCT	National	PCT/US2005/013926	22-Apr-03	WO/2005/106042	10-Nov-05		
10815-8903.AU00	ATL No. 10815-105003 AU	AU	Granted	2005238490	22-Apr-05			2005238490	
10815-8903.BR00	ATL No. 10815-105003 BR	BR	Published	P0508931-0	22-Apr-05		14-Aug-07		
10815-8903.CA00	ATL No. 10815-105003 CA	CA	Pending	2,563,176	22-Apr-05				
10815-8903.CN00	ATL No. 10815-105003 CN	CN	Published	200580619913.7	22-Apr-05	1989947	13-Jun-07		
10815-8903.EP00	ATL No. 10815-105003 EP	EP	Published	05740895.7	22-Apr-05	1745062	24-Jan-07		
10815-8903.IL00	ATL No. 10815-105003 IL	IL	Pending	178564	22-Apr-05				
10815-8903.IN00	ATL No. 10815-105003 IN	IN	Pending	6960/DELNP/2006	22-Apr-05				

Bracket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
	IN								
10815-8003 JP00	ATL No. 10815-105003 JP	JP	Published	2007509694	22-Apr-05	2007534324	29-Nov-07	4718541	
10815-8003 KR00	ATL No. 10815-105003 KR	KR	Published	3020067024518	22-Apr-05	2007-0031907	20-Mar-07		
10815-8003 SG00	ATL No. 10815-105003 SG	SG	Granted	200607333-2	22-Apr-05			126609	30-Apr-09
108015-8003 SG01	ATL No. 10815-105003 SG	SG	Abandoned	200902764-0	22-Apr-05				
MODULATORS OF COAGULATION FACTORS WITH ENHANCED STABILITY									
10815-8004	ATL No. 10815-105013	US	Expired	60725509	11-Oct-05				
10815-8004 US00	ATL No. 10815-105010	US	Granted	115436190	11-Oct-06	US-2008-0125383-A1	29-May-08	7531524	12-May-09
10815-8004 US01	ATL No. 10815-105012	US	Abandoned	11605712	27-Nov-06	2007-0105809	10-May-07		
ADMINISTRATION OF THE REGIANTICOAGULATION SYSTEM									
10815-8005	ATL No. 10815-105011	US	Expired	607808987	26-May-06				
10815-8005 US80	ATL No. 10815-105011	US	Expired	607847809	27-Sep-06				
10815-8005 US01	ATL No. 10815-105011	US	Expired	607865352	10-Nov-06				
10815-8005 US02	ATL No. 10815-105011	US	Published	11805950	25-May-07	US-2009-0048193	19-Feb-09		
10815-8005 WO00	ATL No. 10815-105011	PCT	National	PCT/US2007/012625	25-May-07	WO/2007/140000	06-Dec-07		
10815-8005 EP00	ATL No. 10815-105011 EP	EP	Published	07815043.0	25-May-07	2026653	25-Feb-09		
108015-8005 IN00	ATL No. 10815-105011 IN	IN	Pending	07142:CHENP/2008	25-May-07				
10815-8005 AU00	ATL No. 10815-105011 AU	AU	Pending	2007367801	25-May-07				
10815-8005 BR00	ATL No. 10815-105011 BR	BR	Pending	P0712473.2	25-May-07				
10815-8005 CA00	ATL No. 10815-105011 CA	CA	Pending	2,633,313	25-May-07				
10815-8005 CN00	ATL No. 10815-105011 CN	CN	Published	200780019405.8	25-May-07	101453891	10-Jun-09		
10815-8005 HK00	ATL No. 10815-105011 HK	HK	Published	09107197.7	28-Aug-09	1179540A	04-Dec-09		
10815-8005 IL00	ATL No. 10815-105011 IL	IL	Pending	194991	25-May-07				

47581332_1

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
	IL								
10815-8005 JP00	ATL No. 10815-105011 JP	JP	Published	2009-512183	25-May-07	2009-538325	05-Nov-09		
10815-8005 KR00	ATL No. 10815-105011 KR	KR	Published	1020087030333	25-May-07	2009-0015118	11-Feb-09		
10815-8005 RU00	ATL No. 10815-105011 RU	RU	Pending	2008151758	25-May-07				
10815-8005 SG00	ATL No. 10815-105011 SG	SG	Pending	200808325-5	25-May-07				
10815-8005 UA00	ATL No. 10815-105011 UA	UA	Pending	200814934	25-May-07				
10815-8005 ZA00	ATL No. 10815-105011 ZA	ZA	Pending	2008/09575	25-May-07				
NUCLEIC ACID BINDING COMPOUNDS AS MODULATORS OF PHARMACOLOGICAL AGENTS									
10815-8006 US00	ATL No. 10815-105015	US	Pending	121115322	05-May-08				
10815-8006	ATL No. 10815-105001	US	Expired	60927399	05-May-07				
STEADY-STATE SUBCUTANEOUS ADMINISTRATION OF APTAMERS									
10815-8007	ATL No. 10815-105016	US	Expired	60999080	16-Oct-07				
10815-8007 US00	ATL No. 10815-105016	US	Abandoned	12752994	16-Oct-08	2009-0163437	25-Jun-09		
10815-8007 WO00	ATL No. 10815-105016	PCT	Abandoned	PCT/US2008/080187	16-Oct-08	WO2009/052301	23-Apr-09		
ACTIVELY REVERSIBLE INHIBITORS OF PLATELET PURINERGIC RECEPTORS									
10815-8008	ATL No. 10815-105014	US	Expired	60901060	12-Feb-07				
10815-8008 US00	ATL No. 10815-105014	US	Expired	60901670	13-Feb-07				
10815-8008 US01	ATL No. 10815-105014	US	Expired	61028142	12-Feb-08				
10815-8008 US02	ATL No. 10815-105014	US	Expired	61152064	12-Feb-09				
NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI									
10815-8009	ATL No. 10815-105024	US	Expired	61183847	03-Jun-09				
10815-8009 US01	ATL No. 10815-105040	US	Published	12793572	05-Jun-10	US-2010-0311820	09-Dec-10		

47581232_1

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
10815-8009 WO00	ATL No. 10815-105038 WO	PCT	Published	PCT/US2010/037319	03-Jun-10	WO 2010/141771	09-Dec-10		
10815-8009 US00	ATL No. 10815-105024	US	Expired	61/300,951	03-Feb-10				
CHARACTERIZATION OF OLIGONUCLEOTIDES CONJUGATES									
10815-8010	ATL No. 10815-105025	US	Pending	61/2619,602	16-Nov-09				
10815-8010 WO00	ATL No. 10815-105026	PCT	Pending	PCT/US2009/064650	16-Nov-09				
METHOD FOR MANUFACTURING PEGYLATED OLIGONUCLEOTIDES									
10815-8011	ATL No. 10815-105039	US	Expired	61/327,622	23-Apr-10				
10815-8011 US00	NA	US	Pending	61/479,226	26-Apr-11				
NUCLEIC ACID MODULATORS OF PLATELET GPIIb/IIIa									
10815-8012	ATL No. 10815-105028	US	Pending	61/393,305	14-Oct-10				
NUCLEIC ACID MODULATORS OF CLEC-2									
10815-8013	ATL No. 10815-105034	US	Pending	61/393,191	14-Oct-10				
NUCLEIC MODULATORS OF GROWTH ARREST-SPECIFIC PROTEIN 6 (GAS6)									
10815-8014	ATL No. 10815-105035	US	Pending	61/393,803	15-Oct-10				
NUCLEIC ACID MODULATORS OF ALPHAZETA1									
10815-8015	ATL No. 10815-105036	US	Pending	61/393,815	15-Oct-10				
PHASE 3 STUDY IDEA									
10815-8016	ATL No. 10815-105023	US	Abandoned	61/156,918	03-Mar-09				

47581232_1